We claim:

1. A pharmaceutical composition, *in a unitary dosage form*, comprising anti-bacterial agents and a pharmaceutically acceptable carrier, wherein the anti-bacterial agents consist of ~~a therapeutically effective amount of each of~~ linezolid, bedaquiline, and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof, and ~~a pharmaceutically acceptable carrier~~ the linezolid, bedaquiline, and pretomanid are each present in a unitary dosage form in an amount of 1 mg to 1g.

~~2. The pharmaceutical composition as claimed in claim 1, wherein linezolid is at a dosage of 100 mg/kg.~~

~~3. The pharmaceutical composition as claimed in claim 1, wherein linezolid is at a dosage of 50 mg/kg.~~

~~4. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a plurality of unit dosages, the plurality of unit dosages collectively comprising the therapeutically effective amount of each of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide or a pharmaceutically acceptable salt of each thereof.~~

~~5. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a plurality of unit dosages, the plurality of unit dosages collectively comprising 600 mg or 1200 mg linezolid, 200 to 400 mg bedaquiline, 100 to 200 mg pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof.~~

~~6. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a single unit dosage, the single unit dosage comprising the therapeutically effective amount of each of~~

~~linezolid, bedaquiline and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof.~~

2. The pharmaceutical composition as claimed in claim 1, wherein the linezolid, bedaquiline and pretomanid are each present in the unitary dosage form in an amount of 10 mg to 500 mg.

3. The pharmaceutical composition as claimed in claim 1, wherein the linezolid, bedaquiline and pretomanid are each present in the unitary dosage form in an amount of 50 mg to 300 mg.

4. The pharmaceutical composition as claimed in claim 1, wherein bedaquiline is present in the unitary dosage form in an amount of 200 to 400 mg.

5. The pharmaceutical composition as claimed in claim 1, wherein linezolid is present in the unitary dosage form in an amount of 600 mg.

6. The pharmaceutical composition as claimed in claim 1, wherein pretomanid is present in the unitary dosage form in an amount of 100 to 200 mg.

7. The pharmaceutical composition unitary dosage form as claimed in claim 1, wherein the unitary dosage form is a tablet or capsule.

8. The pharmaceutical composition unitary dosage form as claimed in claim 1, wherein the unitary dosage form comprises 100 mg of pretomanid.

9. The pharmaceutical composition unitary dosage form as claimed in claim 1, wherein the unitary dosage form comprises 200 mg of pretomanid.

10. The pharmaceutical composition unitary dosage form as claimed in claim 1, wherein the unitary dosage form comprises 600 mg of linezolid and 100 mg of pretomanid.

11. The pharmaceutical composition unitary dosage form as claimed in claim 1, wherein the unitary dosage form comprises 600 mg of linezolid and 200 mg of pretomanid.

Dated this 16th day of April 2018

of S. MAJUMDAR & CO.
Applicant's Agent

Compositions of the present invention are administered to a human or other mammal in a safe and therapeutically effective amount as described herein. These safe and therapeutically effective amounts will vary according to the type and size of mammal being treated and the desired results of the treatment. A "therapeutically effective amount"' is an amount effective for treating tuberculosis. The term "treating", with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating can be curing, improving, or at least partially ameliorating the disorder.

Any of the various methods known by persons skilled in the art for packaging tablets, caplets, or other solid dosage forms suitable for oral administration, that will not degrade the components of the present invention, are suitable for use in packaging. The combinations may be packaged in glass and plastic bottles. Tablets, caplets, or other solid dosage forms suitable for oral administration may be packaged and contained in various packaging materials optionally including a dessicant e.g. silica gel. Packaging may be in the form of unit dose blister packaging. ~~For example, a package may contain one blister tray of tenofovir DF and another blister tray of emtricitabine pills, tablets, caplets, or capsule. A patient, would take one dose, e.g. a pill, from one tray and one from the other. Alternatively, the package may contain a blister tray of the co-formulated combination of tenofovir DF and emtricitabine in a single pill, tablet, caplet or capsule. As in other combinations and packaging thereof, the combinations of the invention include physiological functional derivatives of tenofovir DF and FTC~~.

The packaging material may also have labeling and information related to the pharmaceutical composition printed thereon. Additionally, an article of manufacture may contain a brochure, report, notice, pamphlet, or leaflet containing product information. This form of pharmaceutical information is referred to in the pharmaceutical industry as a "package insert." A package insert may be attached to or included with a pharmaceutical article of manufacture. The package insert and any article of manufacture labeling provides information relating to the pharmaceutical composition. The information and labeling provides various forms of information utilized by health-care professionals and patients, describing the composition, its dosage and various other parameters required by regulatory agencies such as the United States Food and Drug Agency.